Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more
Hemostemix Inc (HMTXF) - Total Liabilities
Latest total liabilities as of September 2025: $4.80 Million USD
Based on the latest financial reports, Hemostemix Inc (HMTXF) has total liabilities worth $4.80 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hemostemix Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Hemostemix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hemostemix Inc Competitors by Total Liabilities
The table below lists competitors of Hemostemix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BALAXI PHARMACEUTICALS LIMITED
NSE:BALAXI
|
India | ₹844.30 Million |
|
IMAGIS Co. Ltd
KQ:115610
|
Korea | ₩1.82 Billion |
|
Cubtek Inc.
TWO:2252
|
Taiwan | NT$308.84 Million |
|
Western Bulk Chartering AS
PINK:WSSTF
|
USA | $57.00 Million |
|
Republic Power Group Limited Class A Ordinary Shares
NASDAQ:RPGL
|
USA | $3.70 Million |
|
Berkem Group SA
PA:ALKEM
|
France | €72.73 Million |
|
TBH Global Co Ltd
KO:084870
|
Korea | ₩44.12 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Hemostemix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hemostemix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hemostemix Inc (2013–2024)
The table below shows the annual total liabilities of Hemostemix Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $8.20 Million | +6.65% |
| 2023-12-31 | $7.68 Million | +6.23% |
| 2022-12-31 | $7.23 Million | +23.73% |
| 2021-12-31 | $5.85 Million | +70.87% |
| 2020-12-31 | $3.42 Million | -17.54% |
| 2019-12-31 | $4.15 Million | +253.31% |
| 2018-12-31 | $1.17 Million | +152.68% |
| 2017-12-31 | $464.79K | -87.40% |
| 2016-12-31 | $3.69 Million | +492.45% |
| 2015-12-31 | $622.73K | +12.87% |
| 2014-12-31 | $551.70K | +127.05% |
| 2013-12-31 | $242.98K | -- |